checkAd

    DGAP-News  108  0 Kommentare DEFENCE THERAPEUTICS ACHIEVES A MAJOR MILESTONE AND BEGINS IND-ENABLING TESTING OF ITS ACCUTOX LEAD COMPOUND AGAINST BREAST CANCER - Seite 3



    Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.

    10.01.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.dgap.de

    Language: English
    Company: Defence Therapeutics Inc.
    1680 - 200 Burrard St
    V6C3L6 Vancouver
    Canada
    E-mail: info@defencetherapeutics.com
    Internet: https://defencetherapeutics.com
    ISIN: CA24463V1013
    WKN: A3CN14
    Listed: Regulated Unofficial Market in Frankfurt, Stuttgart; Toronto
    EQS News ID: 1266802

     
    End of News DGAP News Service

    Lesen Sie auch

    1266802  10.01.2022 

    fncls.ssp?fn=show_t_gif&application_id=1266802&application_name=news&site_id=wallstreet
    Seite 3 von 3



    Diskutieren Sie über die enthaltenen Werte



    EQS Group AG
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von EQS Group AG
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    DGAP-News DEFENCE THERAPEUTICS ACHIEVES A MAJOR MILESTONE AND BEGINS IND-ENABLING TESTING OF ITS ACCUTOX LEAD COMPOUND AGAINST BREAST CANCER - Seite 3 DGAP-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE THERAPEUTICS ACHIEVES A MAJOR MILESTONE AND BEGINS IND-ENABLING TESTING OF ITS ACCUTOX LEAD COMPOUND AGAINST BREAST CANCER 10.01.2022 / 13:30 The issuer is solely …

    Artikel zu den Werten

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer